Literature DB >> 3827333

Circulating yersinia specific immune complexes after acute yersiniosis: a follow up study of patients with and without reactive arthritis.

R Lahesmaa-Rantala, K Granfors, R Kekomäki, A Toivanen.   

Abstract

The occurrence of immune complexes (ICs) containing Yersinia enterocolitica antigen and immunoglobulin was studied in 216 serum samples from 51 patients with recent yersiniosis at an early stage of the disease and during a follow up of two to 12 months. Twenty eight of the patients developed reactive arthritis, 23 recovered from the infection without any complications. An enzyme linked immunosorbent assay (ELISA) recently developed for detection of ICs containing yersinia antigen(s) and IgM, IgG, or IgA was applied. During the first two months after onset of the infection yersinia specific IgM complexes were demonstrated in higher concentrations in patients with arthritis than in those not developing this postinfection complication (p less than 0.02). The difference in the occurrence of IgM complexes between the two groups decreased with time. Yersinia specific IgA complexes were demonstrable in four patients with arthritis and in none of the non-arthritic patients. Yersinia specific IgG complexes were occasionally present in both patient groups. Altogether, more than eight months after onset of the infection yersinia specific ICs were detected in six arthritic and two non-arthritic patients, suggesting that in certain individuals yersiniae may hide after the initial infection for prolonged periods.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3827333      PMCID: PMC1002077          DOI: 10.1136/ard.46.2.121

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  IgA-containing immune complexes in patients with psoriatic arthritis.

Authors:  R P Hall; L H Gerber; T J Lawley
Journal:  Clin Exp Rheumatol       Date:  1984 Jul-Sep       Impact factor: 4.473

Review 2.  Immune complexes in human diseases.

Authors:  R C Williams
Journal:  Annu Rev Med       Date:  1981       Impact factor: 13.739

3.  Characterization of sequential immune complexes in infective endocarditis by Western blot analysis.

Authors:  R D Inman; R A Rosenberg; P B Redecha; C L Christian
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

4.  Persistence of circulating HBsAg/IgM complexes in acute viral hepatitis, type B: an early marker of chronic evolution.

Authors:  F Careoda; R de Franchis; A D'Arminio Monforte; M Vecchi; E Rossi; M Primignani; M Palla; N Dioguardi
Journal:  Lancet       Date:  1982-08-14       Impact factor: 79.321

5.  Measurement of immunoglobulin M (IgM), IgG, and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunosorbent assay: persistence of serum antibodies during disease.

Authors:  K Granfors
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

Review 6.  The cross-tolerance hypothesis, HLA-B27 and ankylosing spondylitis.

Authors:  A Ebringer
Journal:  Br J Rheumatol       Date:  1983-11

7.  Detection of circulating Yersinia-immunoglobulin complexes by enzyme immunoassay (EIA).

Authors:  R Lahesmaa-Rantala; K Granfors; A Toivanen
Journal:  J Immunol Methods       Date:  1986-05-22       Impact factor: 2.303

8.  Yersinia enterocolitica infection complicated by glomerulonephritis.

Authors:  J Forsström; M Viander; A Lehtonen; T Ekfors
Journal:  Scand J Infect Dis       Date:  1977

9.  Immune complexes in polyarthritis after Salmonella gastroenteritis.

Authors:  D H Manicourt; S Orloff
Journal:  J Rheumatol       Date:  1981 Jul-Aug       Impact factor: 4.666

10.  Complexes of hepatitis B surface antigen and immunoglobulin M in the sera of patients with hepatitis B virus infection.

Authors:  M Palla; R Rizzi; M Toti; P Almi; M Rizzetto; F Bonino; R Purcell
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

View more
  15 in total

1.  Late complications after a Yersinia enterocolitica epidemic: a follow up study.

Authors:  H Lindholm; R Visakorpi
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

Review 2.  Epidemic reactive arthritis.

Authors:  C J Eastmond
Journal:  Ann Rheum Dis       Date:  1990-02       Impact factor: 19.103

Review 3.  Immunological and bacteriological aspects of reactive arthritis.

Authors:  A Toivanen; K Granfors; R Lahesmaa-Rantala; P Toivanen
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

4.  Response of synovial fluid T cell clones to Yersinia enterocolitica antigens in patients with reactive Yersinia arthritis.

Authors:  E Hermann; B Fleischer; W J Mayet; T Poralla; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

5.  Yersinia specific immune complexes in the synovial fluid of patients with yersinia triggered reactive arthritis.

Authors:  R Lahesmaa-Rantala; K Granfors; H Isomäki; A Toivanen
Journal:  Ann Rheum Dis       Date:  1987-07       Impact factor: 19.103

6.  Decomplementation by cobra venom factor suppresses Yersinia-induced arthritis in rats.

Authors:  K I Gaede; E Baumeister; J Heesemann
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Immune complexes in ankylosing spondylitis.

Authors:  I L MacLean; J R Archer; M I Cawley; B L Kidd; B P O'Hara; F S Pegley; P W Thompson
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  Does reduced erythrocyte C3b receptor (CR1) activity contribute to the pathogenesis of yersinia triggered reactive arthritis?

Authors:  R Lahesmaa; E Eerola; A Toivanen
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  Oxygen radical production and trapping in subjects with previous Yersinia infection.

Authors:  M Ristola; T Metsä-Ketelä; M Leirisalo-Repo; H Repo
Journal:  Inflammation       Date:  1992-06       Impact factor: 4.092

10.  Cationic Yersinia antigen-induced chronic allergic arthritis in rats. A model for reactive arthritis in humans.

Authors:  A K Mertz; S R Batsford; E Curschellas; M J Kist; K B Gondolf
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.